BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1142 related articles for article (PubMed ID: 32720214)

  • 21. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay.
    Pieri M; Nuccetelli M; Nicolai E; Sarubbi S; Grelli S; Bernardini S
    J Med Virol; 2021 Apr; 93(4):2523-2528. PubMed ID: 33463719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
    Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
    J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.
    Zhang X; Lu S; Li H; Wang Y; Lu Z; Liu Z; Lai Q; Ji Y; Huang X; Li Y; Sun J; Wu Y; Xu X; Hou J
    Virol Sin; 2020 Dec; 35(6):820-829. PubMed ID: 33351168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays.
    Qian C; Zhou M; Cheng F; Lin X; Gong Y; Xie X; Li P; Li Z; Zhang P; Liu Z; Hu F; Wang Y; Li Q; Zhu Y; Duan G; Xing Y; Song H; Xu W; Liu BF; Xia F
    Clin Chem Lab Med; 2020 Aug; 58(9):1601-1607. PubMed ID: 32609640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort.
    Kaneko S; Nukui Y; Arashiro T; Aiso Y; Sugii M; Hadano Y; Nagata K; Taki R; Ueda K; Hanada S; Suzaki S; Harada N; Yamaguchi Y; Nakanishi H; Kurosaki M; Nagasawa M; Izumi N
    J Med Virol; 2021 Jan; 93(1):569-572. PubMed ID: 32720704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus.
    Woo PC; Lau SK; Wong BH; Chan KH; Chu CM; Tsoi HW; Huang Y; Peiris JS; Yuen KY
    Clin Diagn Lab Immunol; 2004 Jul; 11(4):665-8. PubMed ID: 15242938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays.
    Kweon OJ; Lim YK; Kim HR; Kim MC; Choi SH; Chung JW; Lee MK
    PLoS One; 2020; 15(10):e0240395. PubMed ID: 33091042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Performance of SARS-CoV-2 IgG and IgM Tests Using an Automated Chemiluminescent Assay.
    Zhou JA; Zeng HL; Deng LY; Li HJ
    Curr Med Sci; 2021 Apr; 41(2):318-322. PubMed ID: 33877548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples.
    Black MA; Shen G; Feng X; Garcia Beltran WF; Feng Y; Vasudevaraja V; Allison D; Lin LH; Gindin T; Astudillo M; Yang D; Murali M; Iafrate AJ; Jour G; Cotzia P; Snuderl M
    J Immunol Methods; 2021 Feb; 489():112909. PubMed ID: 33166549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma.
    Bundschuh C; Egger M; Wiesinger K; Gabriel C; Clodi M; Mueller T; Dieplinger B
    Clin Chim Acta; 2020 Oct; 509():79-82. PubMed ID: 32526218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
    Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System.
    Angeloni S; Cameron A; Pecora ND; Dunbar S
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33900295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA.
    Kulkarni R; Patil HP; Palkar S; Lalwani S; Mishra AC; Arankalle V
    J Virol Methods; 2021 Jan; 287():113996. PubMed ID: 33126149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities.
    Orner EP; Rodgers MA; Hock K; Tang MS; Taylor R; Gardiner M; Olivo A; Fox A; Prostko J; Cloherty G; Farnsworth CW
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115300. PubMed ID: 33388575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of the serum IgM and IgG to SARS-CoV-2 in coronavirus disease-2019.
    Wu LX; Wang H; Gou D; Fu G; Wang J; Guo BQ
    J Clin Lab Anal; 2021 Jan; 35(1):e23649. PubMed ID: 33184940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Tancevski I; Weiss G; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 May; 59(6):1143-1154. PubMed ID: 33554557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2.
    Liu W; Liu L; Kou G; Zheng Y; Ding Y; Ni W; Wang Q; Tan L; Wu W; Tang S; Xiong Z; Zheng S
    J Clin Microbiol; 2020 May; 58(6):. PubMed ID: 32229605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
    Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
    Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay.
    Higgins RL; Rawlings SA; Case J; Lee FY; Chan CW; Barrick B; Burger ZC; Yeo KJ; Marrinucci D
    PLoS One; 2021; 16(3):e0247797. PubMed ID: 33661960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.